AN 448 Sandoz (Mazindol) in the treatment of obesity.
The clinical value of a new anorectic agent, AN 448 Sandoz (mazindol) has been assessed in a double-blind trial against placebo in 50 obese patients. Over the 12 weeks of the trial, mazindol was shown to be an effective adjunct to carbohydrate restriction in weight reduction.
D001835:Body Weight; D002986:Clinical Trials as Topic; D004038:Diet, Reducing; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008454:Mazindol / Q000009:adverse effects / Q000627:therapeutic use*; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000473:pathology; D010919:Placebos
D007211:Indoles; D010919:Placebos; D008454:Mazindol